Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

By E. Morris, S. Jha, C. Restaino, P. Dayananth, Hugh Y. Zhu, A. Cooper, D. Carr, Yongi Deng, Weihong Jin, Stuart Black and 33 more. Cancer Discovery, 2013

615 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/f2272ea16be7be327ca1f16fa3d76e85f13511b6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

1. Nikolaus Schultz
2. Mathew Garnett

In Molecular Biology

1. J. Reis-Filho
2. J. Baselga
3. Nikolaus Schultz
4. Larry Norton
5. Mathew Garnett
6. Bonil Koo
7. Ronglai Shen
8. Sumit Middha

In Oncology

1. C. Der
2. J. Reis-Filho
3. J. Baselga
4. Nikolaus Schultz
5. Larry Norton
6. Bonil Koo
7. C. Hudis
8. M. Scaltriti

Citations in the corpus

• Human Primary Liver Cancer -derived Organoid Cultures for disease modelling and drug screening (2017, positive): “The reason for this difference is unclear, although ERK 462 inhibitors have demonstrated activity in cells with acquired BRAF and MEK inhibitor463 resistance [61].”
• The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers (2018, background): “Moreover, MAPK pathway inhibitors including selective MEK and ERK inhibitors are also under active clinical evaluation in patients with breast and other cancer types (Flaherty et al., 2012; Morris et al., 2013).”
• KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer (2018, background): “Cite this article as Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a031435 w w w .p er sp ec ti ve si n m ed ic in e. o rg inhibitors SCH772984 or ulixertinib/BVD-523 found that ∼50% of PDAC cell lines were sensitive (Morris et al. 2013; Ryan et al. 2015; Hayes et al. 2016).”